肾细胞癌骨转移的预后:来自大型癌症中心的经验
该研究回顾性分析了Gustave Roussy癌症中心1992年4月至2016年3月期间300例肾细胞癌骨转移患者的资料,中位总生存期为23.2个月(95%CI 19.9-26.2)。同步孤立骨转移患者的总生存期优于合并其他转移者(40个月 vs 20个月,P<0.001)。多因素分析显示MSKCC风险组、骨转移数目和根治性切除是重要的预后因素。
要点
- 同步孤立骨转移患者中位OS为40个月,合并其他转移者为20个月(P<0.001)。
- 多因素分析显示合并其他转移是预后不良的预测因素,MSKCC风险组、根治性切除和同步孤立骨转移是更好OS的预测因素。
- 作者认为,初诊肾细胞癌时若存在孤立骨转移而无合并其他转移,应考虑骨外科手术以实现局部肿瘤控制并可能提高OS。
核心结论
- 本研究提示MSKCC评分、骨转移数目和根治性切除是肾细胞癌骨转移患者的重要预后因素。
- 作者认为,初诊肾细胞癌时若存在孤立骨转移而无合并其他转移,应考虑骨外科手术以实现局部肿瘤控制并可能提高OS。
研究设计与样本
- 回顾性收集Gustave Roussy癌症中心1992年4月至2016年3月期间治疗的肾细胞癌骨转移患者数据。
- 从1750例肾细胞癌患者中识别出300例骨转移患者。
- 分析因素包括年龄、性别、ECOG体力状态、MSKCC风险组、组织学、骨病灶数目和部位、合并转移、骨转移治疗及从诊断到骨转移的时间。
- 同步孤立骨转移定义为初诊肾细胞癌时单个骨转移灶且无合并内脏病灶。
- 采用Kaplan-Meier法计算OS,Cox回归模型分析预后因素。
主要发现
- 从诊断到骨转移的中位时间为32.4个月(范围0-324个月)。
- 64例(21%)患者骨为唯一转移部位,22例(7%)患者为同步孤立骨转移,236例(79%)患者合并其他部位转移。
- 中位OS为23.2个月(95%CI 19.9-26.2)。
- 同步孤立骨转移患者OS优于合并其他转移者(40个月 vs 20个月,P<0.001)。
- 多因素分析显示合并其他转移是预后不良的预测因素,MSKCC风险组、根治性切除和同步孤立骨转移是更好OS的预测因素。
临床怎么用
- 作者认为,初诊肾细胞癌时若存在孤立骨转移而无合并其他转移,应考虑骨外科手术以实现局部肿瘤控制并可能提高OS。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bone metastases (BMs) are associated with significant morbidity and shorter survival in renal cell carcinoma (RCC). Our purpose was to identify prognostic factors for overall survival (OS) in RCC patients with BMs. METHODS: Data from patients with BMs from RCC treated at Gustave Roussy between April 1992 and March 2016 were retrospectively collected. Age, sex, Eastern Cooperative Oncology Group-Performance Status, Memorial Sloan-Kettering Cancer Center (MSKCC) risk groups, histology, number and site of bone lesions, concomitant metastases (presence and sites), therapy for BMs (radical resection or palliative surgery, radiotherapy and other local and systemic treatments) and time from diagnosis to BMs were analysed. Synchronous solitary bone metastasis (SSBM) was defined as a single BM without concomitant visceral lesions at the initial diagnosis of RCC. OS was calculated from the date of BMs diagnosis to death or last follow-up using Kaplan-Maier method and modelled with Cox regression analysis. RESULTS: From 1750 patients with diagnosis of RCC followed at Gustave Roussy Cancer Campus, 300 patients with BMs were identified. Median time from diagnosis to BMs was 32.4 months (range 0-324 months). In 64 patients (21%), bone was the only metastatic site, and 22 patients (7%) had an SSBM and 236 patients (79%) had concomitant metastases in other sites. Median OS was 23.2 months (95% confidence interval 19.9-26.2). SSBM patients had better OS than those with concomitant metastases (40 vs 20 months; P < 0.001). At multivariate analysis, concomitant metastases remained predictor of poor prognosis, while MSKCC risk group, radical resection and SSBM were predictors of better OS. CONCLUSIONS: This study suggests that MSKCC score, numbers of BMs and radical resection are important prognostic factors for RCC patients with BMs. Additionally, in the presence of solitary BM without concomitant metastases at the initial diagnosis of RCC, bone surgery should be considered to achieve local tumour control and likely increase OS.
引用
- Ruatta F, Derosa L, Escudier B, et al. Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre. Eur J Cancer. 2018. PMID: 30551078. doi:10.1016/j.ejca.2018.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。